Staphylococcus aureus Resistant to Vancomycin -United States, 2002
Staphylococcus aureus is a cause of hospital-and communityacquired infections (1, 2) . In 1996, the first clinical isolate of S. aureus with reduced susceptibility to vancomycin was reported from Japan (3) . The vancomycin minimum inhibitory concentration (MIC) result reported for this isolate was in the intermediate range (vancomycin MIC=8 µg/mL) using interpretive criteria defined by the National Committee for Clinical Laboratory Standards (4 (5, 6) . This report describes the first documented case of infection caused by vancomycin-resistant S. aureus (VRSA) (vancomycin MIC >32 µg/mL) in a patient in the United States. The emergence of VRSA underscores the need for programs to prevent the spread of antimicrobialresistant microorganisms and control the use of antimicrobial drugs in health-care settings.
In June 2002, VRSA was isolated from a swab obtained from a catheter exit site from a Michigan resident aged 40 years with diabetes, peripheral vascular disease, and chronic renal failure. The patient received dialysis at an outpatient facility (dialysis center A). Since April 2001, the patient had been treated for chronic foot ulcerations with multiple courses of antimicrobial therapy, some of which included vancomycin. In April 2002, the patient underwent amputation of a gangrenous toe and subsequently developed methicillinresistant S. aureus bacteremia caused by an infected arteriovenous hemodialysis graft. The infection was treated with vancomycin, rifampin, and removal of the infected graft. In June, the patient developed a suspected catheter exit-site infection, and the temporary dialysis catheter was removed; cultures of the exit site and catheter tip subsequently grew S. aureus resistant to oxacillin (MIC >16 µg/mL) and vancomycin (MIC >128 µg/mL). A week after catheter removal, the exit site appeared healed; however, the patient's chronic foot ulcer appeared infected. VRSA, vancomycin-resistant Enterococcus faecalis (VRE), and Klebsiella oxytoca also were recovered from a culture of the ulcer. Swab cultures of the patient's healed catheter exit site and anterior nares did not grow VRSA. To date, the patient is clinically stable, and the infection is responding to outpatient treatment consisting of aggressive wound care and systemic antimicrobial therapy with trimethroprim/sulfamethoxazole.
The VRSA isolate recovered from the catheter exit site was identified initially at a local hospital laboratory using commercial MIC testing and was confirmed by the Michigan Department of Community Health and CDC. Identification methods used at CDC included traditional biochemical tests and DNA sequence analysis of gyrA and the gene encoding 16S ribosomal RNA. Molecular tests for genes unique to enterococci were negative. The MIC results for vancomycin, teicoplaninin, and oxacillin were >128 µg/mL, 32 µg/mL, and >16 µg/mL, respectively, by the broth microdilution method. The isolate contained the vanA vancomycin resistance gene from enterococci, which is consistent with the glycopeptide MIC profiles. It also contained the oxacillin-resistance gene mecA. The isolate was susceptible to chloramphenicol linezolid, minocycline, quinupristin/dalfopristin, tetracycline, and trimethoprim/sulfamethoxazole.
Epidemiologic and laboratory investigations are under way to assess the risk for transmission of VRSA to other patients, health-care workers, and close family and other contacts. To date, no VRSA transmission has been identified.
Infection-control practices in dialysis center A were assessed; all health-care workers followed standard precautions consistent with CDC guidelines (7) . After the identification of VRSA, dialysis center A initiated special precautions on the basis of CDC recommendations (8) , including using gloves, gowns, and masks for all contacts with the patient; performing dialysis with a dedicated dialysis machine during the last shift of the day in an area separate from other patients; having a dialysis technician dedicated to providing care for the patient; using dedicated, noncritical patient-care items; and enhancing education of staff members about appropriate infection-control practices. Assessment of infection-control practices in other health-care settings in which the patient was treated is ongoing.
isolated from the swab culture. This VRSA isolate is susceptible in vitro to several antimicrobial agents, including antimicrobials recently approved by the Food and Drug Administration (i.e., linezolid and quinupristin/dalfopristin) with activity against glycopeptide-resistant Gram-positive microorganisms.
In 1997, the Healthcare Infection Control Practices Advisory Committee published guidelines for the prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin (8) ; plans to contain VISA/VRSA on the basis of CDC recommendations have been established in some state health departments. In the health-care setting, a patient with VISA/VRSA should be placed in a private room and have dedicated patient-care items. Health-care workers providing care to such patients should follow contact precautions (i.e., wearing gowns, masks, and gloves and using antibacterial soap for hand washing). These control measures were adopted by dialysis center A immediately following confirmation of the VRSA isolate. To date, there has been no documented spread of this microorganism to other patients or health-care workers.
Strategies to improve adherence to current guidelines to prevent transmission of antimicrobial resistant microorganisms in health-care settings should be a priority for all health-care facilities in the United States. S. aureus should be tested for resistance to vancomycin using a MIC method. The isolation of S. aureus with confirmed or presumptive vancomycin resistance should be reported immediately through state and local health departments to the Division of Healthcare Quality Promotion, National Center for Infectious Diseases, CDC, telephone 800-893-0485. In late July 2001, the National Oceanographic and Atmospheric Association (NOAA) reported temperatures averaging 5º F (-15º C)-10º F (-12º C) above normal in the southern plains states (2) . The intense heat and humidity prompted NOAA's National Weather Service to issue heat advisories* in Missouri, New Mexico, Oklahoma, and Texas (2; Missouri Department of Health and Senior Services, personal communication 2002). During July-August 2001, a total of 95 deaths was attributed to excessive natural heat in the affected states. Provisional mortality statistics were obtained from the vital statistics section of each state, and information about underlying cause of death, age, sex, date of death, and contributing causes were provided. Peak mortality occurred during the reported 8-day heat advisory period ( Figure 1 ). Six (6%) deaths occurred among children aged <4 years and 42 (41%) among persons aged >75 years; 69 (73%) deaths occurred among males.
Case Reports
Case 1. In Oklahoma in mid-July 2001, a man aged 29 years was found disoriented and wandering in a commercial parking lot. He apparently had fallen and had abrasions on his knees and a broken tooth. In the emergency department, he was semiconscious but combative. His rectal temperature increased from 105.4º F (40.7º C) to 107.8º F (42.1º C) in <1 hour. Despite medical treatment for hyperthermia, he was pronounced dead 22 hours after being found. Laboratory tests at autopsy were positive for cocaine and alcohol. The medical examiner attributed the cause of death to heat-related illness.
Case 2. In Oklahoma in mid-July 2001, police were called to check on a man aged 62 years with a history of alcoholism, heavy smoking, and poor diet who had not been seen for 7 days. The man was found dead by the police in his home, which was very hot; an ambient temperature was not recorded. A fan and air-conditioning unit in the home were in working order but turned off. Postmortem blood alcohol level was 0.07%. Following an autopsy, the death was attributed to hyperthermia.
Case 3. In Texas in late July 2001, a boy aged 2 years was found in a motor vehicle with the windows rolled up for an undetermined length of time. The boy had locked himself in the car and could not get out. The temperature inside the car was not measured, nor was the outside temperature recorded; however, the high temperatures in central Texas during this time ranged from the mid-to-high 90s. The boy arrived at the hospital with an oral temperature of 102º F (39º C) and died 2 days later. The death was attributed to heatstroke.
Case 4. In a border town in Chihuahua State, Mexico, in August 2001, a man aged 21 years was found collapsed and incoherent on the street. A witness reported that he had complained about abdominal pain and vomiting. He arrived at an emergency department in New Mexico 3 hours after he was found. His rectal temperature was 105.7º F (40.9º C). The patient had laboratory evidence of rhabdomyolysis, severe dehydration, and renal failure. Blood alcohol level and a screen for drugs were negative. He died 3 hours after arrival at the hospital. Cause of death was attributed to hyperthermia due to environmental heat exposure. High temperature at the border that day was 90º F (32º C).
United States
During 1979-1999, a total of 8,015 deaths in the United States was associated with excessive heat exposure † , 3,829 (48%) were "due to weather conditions," 377 (5%) were "of man-made origins" (i.e., heat generated in vehicles, kitchens, boiler rooms, furnace rooms, and factories), and 3,809 (48%) were "of unspecified origin" (3); 182 deaths per year (range: 54-651) were associated with excessive heat due to weather conditions. Of the 3,764 (98%) deaths specified as due to weather conditions with a reported age (3), 142 (4%) occurred among children aged <4 years, and 1,068 (28%) occurred among persons aged >75 years ( Figure 2 ). Editorial Note: The cases summarized in this report demonstrate risk factors for heat-related illness. Heat-related illnesses include sunburn, heat cramps, heat rash, heat exhaustion, and heatstroke. Of these, the two most serious types of heatrelated illness are heat exhaustion and heatstroke, both of †Underlying cause of death during 1979-1998 is classified according to the International Classification of Disease, Ninth Revision (ICD-9). Excessive heat has three categories: E900.0 "due to weather conditions," E900.1 "of manmade origins," and E900.9 "of unspecified origin." The data for 1999 are from ICD-10; code X30 "exposure to excessive natural heat" was added to the 1979-1998 ICD-9 code E900.0, "excessive heat due to weather conditions." which can result in death. Symptoms of heat exhaustion include heavy sweating, muscle cramps, fatigue, weakness, paleness, cold or clammy skin, dizziness, headache, nausea or vomiting, and fainting. Untreated heat exhaustion can progress to heatstroke (4) . Even with prompt medical care, 15% of heatstroke cases are fatal (5) .
Symptoms of heatstroke include a high body temperature (oral temperature of >103º F [>39.4º C] or a rectal temperature of 106º F [41.1º C]); red, hot, dry skin and no sweating; rapid pulse; throbbing headache; dizziness; nausea; confusion; disorientation; delirium; and coma. Heatstroke can occur in the absence of physical exertion. Infants, elderly persons, socially isolated persons, bedridden persons, and persons with certain mental and chronic illnesses are at highest risk (6, 7) . The elderly, especially those aged >80 years, are susceptible to heat-related illness because they are less able to adjust to physiologic changes (e.g., vasodilation) that occur with exposure to excessive heat and are more likely to be taking medication for chronic illness (e.g., tranquilizers and anticholinergics) that increase the risk for heat-related illness (5) . Infants also are sensitive to heat. Conditions such as mild fever can progress quickly to heatstroke if heat stress occurs. Parents and other caregivers should provide adequate hydration during summer months and refrain from dressing children too warmly (5) . Adults also should keep well hydrated during summer months.
Heatstroke also can occur in young, healthy persons who are exercising (6) , because physical exertion during hot weather increases the likelihood of fainting and cramps caused by increased blood flow to the extremities (5). Onset of heatstroke can be rapid and is considered a medical emergency.
The findings in this report are subject to at least three limitations. First, information on decedents is provided by surrogates, who might not accurately describe characteristics or behavior of the decedents. Second, heat-related deaths due to weather conditions or exposure to excessive natural heat might represent only a portion of actual heat-related deaths. These deaths often are a diagnosis of exclusion and can be misclassified as a stroke or heart attack. Deaths attributed to cardiovascular and respiratory disease increase following heat waves (8) . In addition, jurisdictions might use different definitions of heat-related death. Finally, ICD-10 coding was introduced in 1999 and might not be comparable with previous data for 1979-1998.
To reduce morbidity and mortality from heat-related illness, many cities have developed emergency response plans. Local officials use meteorologic information and assess population characteristics to implement prevention strategies (7) . Spending time in an air-conditioned area is the strongest factor in preventing heat-related deaths (1, 9) . The use of fans does not appear to be protective during periods of high heat and humidity (1) . If exposure to heat cannot be avoided, prevention measures should include reducing or eliminating strenuous activities or rescheduling them for cooler parts of the day; drinking water or nonalcoholic fluids frequently; taking cool showers frequently; wearing lightweight, lightcolored, loose-fitting clothing; and avoiding direct sunshine (9) .
Public health messages disseminated to all age groups can make the public aware of the signs and symptoms of heatrelated illness. Prevention messages delivered as early as possible in the media can prevent heat-related illness, injury, and death (1) .
Because many heat-related illnesses and deaths occur among the elderly population, older persons should be encouraged to take advantage of air-conditioned environments (e.g., shopping malls, senior centers, and public libraries) for part of the day. Parents and other caregivers should be educated about the heat sensitivity of children aged <5 years (5).
Injuries and Deaths Among Children Left Unattended in or Around Motor Vehicles -United States, July 2000-June 2001
National attention concerning motor vehicles (MVs) and child safety has focused largely on protecting children as occupants transported in traffic on public roads. However, children who are unattended in or around MVs that are not in traffic also are at increased risk for injury and death. CDC and the nonprofit Trauma Foundation examined data from two databases on both nonfatal and fatal nontraffic MVrelated incidents. This report summarizes the results of that analysis, highlights the major causes of this type of childhood death and injury, and underscores the need for effective interventions.
Nationally representative data on nonfatal injuries treated in hospital emergency departments (EDs) from the National Electronic Injury Surveillance System All Injury Program (NEISS-AIP) were examined (1). Data on fatal injuries occurring across the country were reported from a database developed by the Trauma Foundation's KIDS 'N CARS™ program. During July 2000-June, 2001, data from these two programs documented an estimated 9,160 nonfatal injuries and 78 fatal injuries among children aged <14 years who were left unattended in or around MVs that were not in traffic.
NEISS-AIP, which is operated by the U.S. Consumer Product Safety Commission, collects data annually on approximately 500,000 cases from a nationally representative sample of 65 hospital EDs in the United States. National estimates of nonfatal injuries treated in hospital EDs were calculated by using the sum of sample weights of study cases; weights were derived based on the inverse of the probability of selection; confidence intervals (CIs) were computed by using a direct variance estimation procedure (1). Population estimates for computing rates were obtained from the U.S. Bureau of Census.
NEISS-AIP study case-patients were children treated in a U.S. hospital ED after being injured while left unattended in or around MVs (e.g., cars, trucks, vans, and SUVs) not in traffic. These nontraffic injuries included those associated with 1) parked MVs on or off the street and 2) MVs in motion off the street. Children injured during the normal course of getting in or out of stationary MVs were excluded.
NEISS-AIP obtains data routinely for each nonfatal injury on the principal diagnosis, body part primarily affected, ED discharge disposition, and locale of occurrence (e.g., home or public place). Narratives describing each injury event were used to identify the surface where the incident occurred (e.g., driveway, parking lot, or street) and type of event. A classification scheme assigned cases to the following types of events: run over or backed over by an MV, struck by an MV, fell out of an MV in motion, or fell off of the exterior of an MV (e.g., the bed of a pick-up truck), and other specified (e.g., bumped against, dragged by, submerged in, or overheated in an MV).
The KIDS 'N CARS™ database was used to describe specific incidents involving children aged <14 years who died as a result of being left unattended in or around MVs. National estimates of fatalities cannot be derived from this database. KIDS 'N CARS™ identifies cases through 1) online searches of LexisNexis™, a service providing access to thousands of newspapers and magazines worldwide; 2) keyword searches on Internet search engines, the registration of keyword preferences with Internet providers and news media sites, and searches within archives of newspaper websites; 3) news accounts from a clipping service; 4) contacts with child death review teams; and 5) information from an informal nationwide network of professional and personal contacts. Documentation from news media archives and other record sources is used to validate all cases identified.
A total of 192 NEISS-AIP study cases was identified, representing a national estimate of 9,160 (95% CI=5,344-12,976) children with nonfatal injuries treated in U.S. hospital EDs during July 2000-June 2001. Approximately 42% of injured children were aged <4 years, and 61.9% were male (Table 1) . Injuries occurred predominantly to the head and neck region (30.4%) and the extremities (53.1%). Most (56.8%) injuries were minor contusions and abrasions; however, more serious injuries also were common (26.5% were fractures or internal injuries). Most (81.8%) injured children were treated and released from the ED. Most injuries occurred near the home (47.8%) or on public property (31.1%). Injuries occurred in driveways and parking lots in at least 27.2% of incidents ( Table 2 ). The most common type of nonfatal incident was being struck by an MV, followed by being run over or backed over by an MV and falling out or off of an MV. For nonfatal incidents, approximately 70% of MVs were moving at a slow speed (e.g., moving forward or backward shortly after being set in motion), and approximately 20% were moving backward. The KIDS 'N CARS™ database provided information on 78 children who died during July 2000-June 2001 in 76 separate incidents. Fatalities occurred in 28 states and the District of Columbia. Of the fatally injured children, 64 (82.1%) were aged <4 years, and 42 (53.8%) were male. In 57 (73.1%) cases, the MV was located near a home (e.g., driveway, unpaved area near home, or street in front of home); in 39 (50%) cases, the child lived at that home. The driver was the parent in 12 (57.1%) of the 21 cases in which a child was backed over. The most common type of fatal incident was exposure to excessive heat inside an MV (e.g., when a child was left inside an MV during hot weather) (34.6%), followed by being backed over and being hurt when a child put an MV in motion (26.9%). Approximately 82% of fatal injuries occurred among children aged <4 years (Figure) . However, the nontraffic-related incidents described in this report are an important cause of injuries and deaths among children. These incidents are preventable, and effective interventions must be determined to protect children. The findings in this report are subject to at least six limitations. First, NEISS-AIP captures only injuries treated in hospital EDs and does not include children seen in physicians' offices and clinics. Second, NEISS-AIP provides statistically valid national estimates but not state and local estimates. Third, types of nonfatal incidents were classified by using brief narratives transcribed from medical records; further details about each incident were not available. Fourth, KIDS 'N CARS™ data are not population-based and probably undercount the true number of fatal cases nationally. Fifth, media coverage of these incidents might contain incomplete information and might be less common in large urban areas. Finally, online media archives might exclude very smallcirculation local newspapers. Because of these limitations, methods should be explored to obtain routine national data useful for characterizing and monitoring detailed circumstances of injuries and deaths from all types of nontraffic MVrelated incidents involving children. The National Highway Traffic Safety Administration is assessing methods to identify cases of nontraffic MV-related injuries and deaths in children and to obtain details about injury-related circumstances (2) .
The findings in this report are consistent with other studies that indicate that children left unattended in or around MVs are at increased risk for injury and death in incidents that involve parked MVs, slow-moving MVs, MVs moving backward in driveways and parking lots, MVs set in motion by a child, and trunk entrapment (3) (4) (5) (6) (7) (8) (9) (10) . In this report, excessive heat exposure while in an MV was the most common cause of death; however, scientific literature examining the circumstances of such incidents is minimal.
Several areas for possible intervention include education, legislation, regulation, and changes in vehicle design. Education campaigns aimed at parents and caregivers should communicate the following: 1) ensure adequate supervision when children are playing in areas near parked MVs; 2) never leave children alone in an MV, even when they are asleep or restrained; and 3) keep MVs locked in a garage or driveway and keep keys out of children's reach.
Laws related to endangering the life or health of a child by leaving the child unattended in an MV have been enacted by 11 states; the nature of these laws and associated penalties vary by state. In California, funds from 70% of fines resulting from noncompliance with its associated law will go to counties to support public education campaigns to address these preventable deaths and injuries.
Children might be protected further by commercially available vehicle enhancements, such as sensors that detect unseen obstacles behind an MV or devices that emit audible signals when an MV is in reverse. Evaluation of such interventions should be conducted to inform policy makers about their effectiveness in reducing nontraffic MV-related injuries and deaths among children.
Organization (WHO) is free of indigenous wild poliovirus transmission. The last known case in EUR of polio caused by indigenous wild poliovirus transmission occurred in southeast Turkey in November 1998. EUR comprises 51 countries with an estimated population of 873 million and is the third of the six WHO regions to be certified as polio-free, following the Americas Region in 1994 (1) and the Western Pacific Region in 2000 (2) (Figure) . An estimated 3.4 billion persons (55% of the world's population) live in countries and territories certified free of endemic polio.
The Commission completed a 4-year review of programmatic data compiled by national certification committees to ensure that the absence of reported wild poliovirus isolation reflected interruption of indigenous wild transmission. The prerequisite for regional certification is the absence of indigenous wild poliovirus isolation for at least 3 years (3). Other criteria used to certify that regions are polio-free include 1) high vaccination coverage rates in all countries and within all areas of a country, 2) sensitive surveillance for acute flaccid paralysis (AFP) meeting standard performance indicators † and/or other means of sensitive virologic surveillance, 3) a plan of action to respond to imported cases of wild poliovirus, and 4) political commitment by national governments to maintain high levels of vaccination coverage and surveillance through global certification of polio eradication. In addition, the Commission sought evidence of substantial progress in the process of laboratory containment of wild poliovirus in each country.
In 1988, the Global Polio Eradication Initiative was launched by the World Health Assembly; the initiative is coordinated by WHO in primary partnership with Rotary International, the United Nations Children's Fund (UNICEF), and CDC. National governments, private foundations, nongovernment organizations, corporations, and volunteers are collaborating to achieve eradication. During 2001, a total of 10 countries in three WHO regions (African, Eastern Mediterranean, and Southeast Asia) reported transmission of wild poliovirus (4).
Until polio is eradicated globally, all polio-free countries are at risk for wild poliovirus importation. In EUR, this risk was underscored by the discovery of poliovirus in Bulgaria (5) and Georgia in 2001 § . During 2000-2001, two outbreaks of polio caused by circulating vaccine-derived poliovirus were documented among populations with low vaccination coverage on the island of Hispaniola (the Dominican Republic and Haiti) and the Philippines (6) . Polio-free countries should maintain high levels of polio vaccination coverage and sensitive surveillance for the prompt detection of any circulating poliovirus. To minimize the risk for poliovirus spread, supplementary vaccination campaigns will continue in high-risk areas of some EUR countries. Many of these campaigns are synchronized with those of countries of the Eastern Mediterranean Region (EMR). During 1995-2002, Operation MECACAR (Eastern Mediterranean, Caucasus, and Central Asian Republics) coordinated polio eradication activities among 18 EUR and EMR countries; this effort represented a major advance toward eliminating virus circulation (7, 8 
Notice to Readers

Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young ChildrenUnited States, 2002
On May 14, 2002, the Food and Drug Administration (FDA) approved for use an additional combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (DAPTACEL™ Aventis Pasteur, Ltd. [Toronto, Ontario] ) for the first 4 doses of the diphtheria and tetanus toxoids and pertussis vaccination (DTP) series administered to infants and children aged 6 weeks-6 years (before seventh birthday). DAPTACEL™ is the fifth acellular pertussis vaccine to be licensed for use among infants and young children in the United States. Of these five, three (Tripedia ® , Infanrix™, and DAPTACEL™) are distributed in the United States.
DAPTACEL™ is approved for administration as a 4-dose series at ages 2, 4, 6, and 17-20 months. The Advisory Committee on Immunization Practices (ACIP), the Committee on Infectious Diseases, the American Academy of Pediatrics, and the American Academy of Family Physicians recommend that children routinely receive a series of 5 doses of vaccine against diphtheria, tetanus, and pertussis before age 7 years (1,2). The first 4 doses should be administered at ages 2, 4, 6, and 15-18 months and the fifth dose at age 4-6 years. The customary age for the first dose is 2 months, but it may be given as early as age 6 weeks and up to the seventh birthday. The interval between the third and the fourth dose should be at least 6 months. Data are insufficient to evaluate the use of DAPTACEL™ as a fifth dose among children aged 4-6 years who have received DAPTACEL™ for the previous 4 doses. DAPTACEL™ may be used to complete the vaccination series in infants who have received 1 or more doses of wholecell pertussis DTP.
The following evidence supports the use of DAPTACEL™ for the first 4 doses of the diphtheria, tetanus, and pertussis vaccination series:
1. The rates of local reactions, fever, and other common systemic symptoms following receipt of DAPTACEL™ inoculations were substantially lower than those following whole-cell pertussis vaccination (administered as DTP for doses 1-3 in controlled clinical studies (3,4).
2. Efficacy of 3 doses of DAPTACEL™ against pertussis disease was assessed in a double-blind, randomized, placebocontrolled trial in Sweden (3). Infants were assigned randomly to be vaccinated with either DAPTACEL™, another investigational acellular pertussis vaccine, whole-cell pertussis DTP vaccine, or DT vaccine as placebo at ages 2, 4, and 6 months. The mean length of follow-up was 2 years after the third dose of vaccine. In this trial, pertussis was defined according to the World Health Organization case definition (i.e., a paroxysmal cough illness lasting >21 days and confirmed by culture, serology, or epidemiologic link to a culture-positive household contact). The vaccine efficacy of DAPTACEL™ against WHO-defined pertussis was 84.9% (95% confidence interval [CI]=80.1%-88.6%) (3, 4) . The protective efficacy of DAPTACEL™ against mild pertussis (i.e., >1 day of cough with laboratory confirmation) was 77.9% (95% CI=72.6%-82.2%) (4) . Although a serologic correlate of protection for pertussis has not been established, the antibody responses to the pertussis antigens in DAPTACEL™ among North American infants after 4 doses at ages 2, 4, 6, and 17-20 months was comparable to that achieved among Swedish infants in whom efficacy was demonstrated after three doses at age 2, 4, and 6 months (4).
Because of the reduced frequency of adverse reactions and demonstrated efficacy, ACIP recommends DTaP for all 5 doses of the routine diphtheria, tetanus, and pertussis vaccination series and for the remaining doses in the series for children who have started the vaccination series with whole-cell DTP vaccine (1) . ACIP considers the data to be insufficient in terms of safety and efficacy to express a preference among different acellular pertussis vaccine formulations.
Whenever feasible, the same DTaP vaccine should be used throughout the entire vaccination series. Data are limited on the safety, immunogenicity, or efficacy of different DTaP vaccines when administered interchangeably in the primary or booster vaccination of a child. However, if the vaccine provider does not know or have available the type of DTaP vaccine the child to be vaccinated had received previously, any of the licensed DTaP vaccines may be used to complete the vaccination series (1). 
